Article
Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Anticancer research - 1 Feb 2017
Backman Samuel, Norlén Olov, Eriksson Barbro, Skogseid Britt, Stålberg Peter, Crona Joakim
Abstract excerpt
Mutations affecting the mechanistic target of rapamycin (MTOR) signalling pathway are frequent in human cancer and have been identified in up to 15% of pancreatic neuroendocrine tumours (NETs). Grade A evidence supports the efficacy of MTOR inhibition with everolimus in pancreatic NETs. Although a significant proportion of patients experience disease stabilization, only a minority will show objective tumour...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.